Bifidobacterium animalis subspecies lactis HN019 can reduce the sequelae of experimental periodontitis in rats modulating intestinal parameters, expression of lipogenic genes, and levels of hepatic steatosis
André L. G. Moreira
Department of Oral and Maxillofacial Surgery and Periodontology, School of Dentistry of Ribeirão Preto, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Search for more papers by this authorGiselle A. Silva
Department of Oral and Maxillofacial Surgery and Periodontology, School of Dentistry of Ribeirão Preto, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Search for more papers by this authorPedro H. F. Silva
Department of Oral and Maxillofacial Surgery and Periodontology, School of Dentistry of Ribeirão Preto, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Search for more papers by this authorSérgio L. Salvador
Department of Clinical Analyses, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Search for more papers by this authorRaphael M. Vicente
Department of Oral and Maxillofacial Surgery and Periodontology, School of Dentistry of Ribeirão Preto, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Search for more papers by this authorGraziele C. Ferreira
Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Search for more papers by this authorJose E. Tanus-Santos
Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Search for more papers by this authorMarcia P. A. Mayer
Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
Search for more papers by this authorKarin H. Ishikawa
Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
Search for more papers by this authorSérgio Luís Scombatti de Souza
Department of Oral and Maxillofacial Surgery and Periodontology, School of Dentistry of Ribeirão Preto, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Search for more papers by this authorCorresponding Author
Flávia A. C. Furlaneto
Department of Oral and Maxillofacial Surgery and Periodontology, School of Dentistry of Ribeirão Preto, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Correspondence
Flávia A. C. Furlaneto, Av. Café s/n, Ribeirão Preto, São Paulo 14020-150, Brazil.
Email: [email protected]
Search for more papers by this authorMichel R. Messora
Department of Oral and Maxillofacial Surgery and Periodontology, School of Dentistry of Ribeirão Preto, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Search for more papers by this authorAndré L. G. Moreira
Department of Oral and Maxillofacial Surgery and Periodontology, School of Dentistry of Ribeirão Preto, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Search for more papers by this authorGiselle A. Silva
Department of Oral and Maxillofacial Surgery and Periodontology, School of Dentistry of Ribeirão Preto, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Search for more papers by this authorPedro H. F. Silva
Department of Oral and Maxillofacial Surgery and Periodontology, School of Dentistry of Ribeirão Preto, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Search for more papers by this authorSérgio L. Salvador
Department of Clinical Analyses, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Search for more papers by this authorRaphael M. Vicente
Department of Oral and Maxillofacial Surgery and Periodontology, School of Dentistry of Ribeirão Preto, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Search for more papers by this authorGraziele C. Ferreira
Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Search for more papers by this authorJose E. Tanus-Santos
Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Search for more papers by this authorMarcia P. A. Mayer
Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
Search for more papers by this authorKarin H. Ishikawa
Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
Search for more papers by this authorSérgio Luís Scombatti de Souza
Department of Oral and Maxillofacial Surgery and Periodontology, School of Dentistry of Ribeirão Preto, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Search for more papers by this authorCorresponding Author
Flávia A. C. Furlaneto
Department of Oral and Maxillofacial Surgery and Periodontology, School of Dentistry of Ribeirão Preto, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Correspondence
Flávia A. C. Furlaneto, Av. Café s/n, Ribeirão Preto, São Paulo 14020-150, Brazil.
Email: [email protected]
Search for more papers by this authorMichel R. Messora
Department of Oral and Maxillofacial Surgery and Periodontology, School of Dentistry of Ribeirão Preto, University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil
Search for more papers by this authorAbstract
Objective
To determine whether Bifidobacterium animalis subspecies lactis HN019 (B. lactis HN019) can reduce the sequelae of experimental periodontitis (EP) in rats modulating systemic parameters.
Background
This study evaluated the effects of probiotic therapy (PROB) in the prevention of local and systemic damage resulting from EP.
Methods
Forty-eight rats were allocated into four groups: C (control), PROB, EP, and EP-PROB. PROB (1 × 1010 CFU/mL) administration lasted 8 weeks and PE was induced on the 7th week by placing ligature on the animals' lower first molars. All animals were euthanized in the 9th week of the experiment. Biomolecular analyses, RT-PCR, and histomorphometric analyses were performed. The data obtained were analyzed statistically (ANOVA, Tukey, p < .05).
Results
The EP group had higher dyslipidemia when compared to the C group, as well as higher levels of insulin resistance, proteinuria levels, percentages of systolic blood pressure, percentage of fatty hepatocytes in the liver, and expression of adipokines was up-regulated (LEPR, NAMPT, and FABP4). All these parameters (except insulin resistance, systolic blood pressure, LEPR and FABP4 gene expression) were reduced in the EP-PROB group when compared to the EP group. The EP group had lower villus height and crypt depth, as well as a greater reduction in Bacteroidetes and a greater increase in Firmicutes when compared to the EP-PROB group. Greater alveolar bone loss was observed in the EP group when compared to the EP-PROB group.
Conclusion
Bifidobacterium lactis HN019 can reduce the sequelae of EP in rats modulating intestinal parameters, attenuating expression of lipogenic genes and hepatic steatosis.
CONFLICT OF INTEREST STATEMENT
All authors state explicitly that there are no conflicts of interes in connection with this article.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
REFERENCES
- 1Page RC, Kornman KS. The pathogenesis of human periodontitis: an introduction. Periodontology 2000. 1997; 14: 9-11.
- 2Salvi GE, Lang NP. Host response modulation in the management of periodontal diseases. J Clin Periodontol. 2005; 32(Suppl 6): 108-129.
- 3Hajishengallis G, Lamont RJ. Beyond the red complex and into more complexity: the polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology. Mol Oral Microbiol. 2012; 27: 409-419.
- 4Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RLJr. Microbial complexes in subgingival plaque. J Clin Periodontol. 1998; 25: 134-144.
- 5Nibali L, Tatarakis N, Needleman I, et al. Clinical review: association between metabolic syndrome and periodontitis: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013; 98: 913-920.
- 6Gomes-Filho IS, Balinha I, da Cruz SS, et al. Moderate and severe periodontitis are positively associated with metabolic syndrome. Clin Oral Investig. 2021; 25: 3719-3727.
- 7Golub LM, Lee HM. Periodontal therapeutics: current host-modulation agents and future directions. Periodontology 2000. 2020; 82: 186-204.
- 8Hajishengallis G, Chavakis T, Lambris JD. Current understanding of periodontal disease pathogenesis and targets for host-modulation therapy. Periodontology 2000. 2020; 84: 14-34.
- 9Preshaw PM. Host modulation therapy with anti-inflammatory agents. Periodontology 2000. 2018; 76: 131-149.
- 10Bartold PM, Van Dyke TE. Host modulation: controlling the inflammation to control the infection. Periodontology 2000. 2017; 75: 317-329.
- 11Chatterjee D, Chatterjee A, Kalra D, Kapoor A, Vijay S, Jain S. Role of adjunct use of omega 3 fatty acids in periodontal therapy of periodontitis. A systematic review and meta-analysis. J Oral Biol Craniofac Res. 2022; 12: 55-62.
- 12Trindade-da-Silva CA, Bettaieb A, Napimoga MH, et al. Soluble epoxide hydrolase pharmacological inhibition decreases alveolar bone loss by modulating host inflammatory response, RANK-related signaling, endoplasmic reticulum stress, and apoptosis. J Pharmacol Exp Ther. 2017; 361: 408-416.
- 13Sánchez B, Delgado S, Blanco-Míguez A, Lourenço A, Gueimonde M, Margolles A. Probiotics, gut microbiota, and their influence on host health and disease. Mol Nutr Food Res. 2017; 61:1600240.
- 14Hill C, Guarner F, Reid G, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014; 11: 506-514.
- 15Haffajee AD, Cugini MA, Dibart S, Smith C, Kent RLJr, Socransky SS. The effect of SRP on the clinical and microbiological parameters of periodontal diseases. J Clin Periodontol. 1997; 24: 324-334.
- 16Invernici MM, Furlaneto FAC, Salvador SL, et al. Bifidobacterium animalis subsp lactis HN019 presents antimicrobial potential against periodontopathogens and modulates the immunological response of oral mucosa in periodontitis patients. PLoS One. 2020; 15:e0238425.
- 17Invernici MM, Salvador SL, Silva PHF, et al. Effects of Bifidobacterium probiotic on the treatment of chronic periodontitis: a randomized clinical trial. J Clin Periodontol. 2018; 45: 1198-1210.
- 18Messora MR, Oliveira LF, Foureaux RC, et al. Probiotic therapy reduces periodontal tissue destruction and improves the intestinal morphology in rats with ligature-induced periodontitis. J Periodontol. 2013; 84: 1818-1826.
- 19Silva GA, Moreira ALG, Silva PHF. The use of probiotics can reduce the severity of experimental periodontitis in rats with metabolic syndrome: an immunoenzymatic and microtomographic study. J Periodontol. 2022; 93(2): e1-e12.
- 20Oliveira LFF, Salvador SL, Silva PHF, et al. Benefits of Bifidobacterium animalis subsp. lactis probiotic in experimental periodontitis. J Periodontol. 2017; 88: 197-208.
- 21Oliveira LFF, Silva PHF, Salvador SL, Ervolino E, Casarin R, Figueiredo L, Ricoldi MT, de Souza SLS, Furlaneto F, Messora MR. Probiotic consumption can modify the resilience of periodontal tissues in rats under experimental periodontitis. J Periodontol. 2023; 94(2): 217-229. doi: 10.1002/JPER.21-0555
- 22Oliveira LF, Salvador SL, Silva PH, et al. Benefits of Bifidobacterium animalis subsp. lactis probiotic in experimental periodontitis. J Periodontol. 2017; 88: 197-208.
- 23Ricoldi MST, Furlaneto FAC, Oliveira LFF, et al. Effects of the probiotic Bifidobacterium animalis subsp. lactis on the non-surgical treatment of periodontitis. A histomorphometric, microtomographic and immunohistochemical study in rats. PLoS One. 2017; 12:e0179946.
- 24Oliveira LFF, da Silva GA, Silva PHF, et al. Comparison between different delivery vehicles for the probiotic Bifidobacterium animalis subsp. lactis HN019 on experimental periodontitis in rats. Probiotics Antimicrob Proteins. 2022; 14(2): 313-325.
- 25Lourenςo TGB, Spencer SJ, Alm EJ, Colombo APV. Defining the gut microbiota in individuals with periodontal diseases: an exploratory study. J Oral Microbiol. 2018; 10:1487741.
- 26Huang Y, Liao Y, Luo B, Li L, Zhang Y, Yan F. Non-surgical periodontal treatment restored the gut microbiota and intestinal barrier in apolipoprotein E−/− mice with periodontitis. Front Cell Infect Microbiol. 2020; 10: 498.
- 27Dubinkina VB, Tyakht AV, Odintsova VY, et al. Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease. Microbiome. 2017; 5: 141.
- 28Patel D, Sharma D. Gut microbiota: target for modulation of gut-liver-adipose tissue axis in ethanol-induced liver disease. Mediators Inflamm. 2022; 2022:4230599.
- 29Ferrere G, Wrzosek L, Cailleux F, et al. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice. J Hepatol. 2017; 66: 806-815.
- 30Vasconcelos DF, Pereira da Silva FR, Pinto ME, et al. Decrease of pericytes is associated with liver disease caused by ligature-induced periodontitis in rats. J Periodontol. 2017; 88: e49-e57.
- 31Andrade RSB, França LFC, Pessoa LDS, et al. High-fat diet aggravates the liver disease caused by periodontitis in rats. J Periodontol. 2019; 90: 1023-1031.
- 32Le TK, Hosaka T, Nguyen TT, et al. Bifidobacterium species lower serum glucose, increase expressions of insulin signaling proteins, and improve adipokine profile in diabetic mice. Biomed Res. 2015; 36: 63-70.
- 33Choi WJ, Dong HJ, Jeong HU, et al. Lactobacillus plantarum LMT1-48 exerts anti-obesity effect in high-fat diet-induced obese mice by regulating expression of lipogenic genes. Sci Rep. 2020; 10: 869.
- 34Bagarolli RA, Tobar N, Oliveira AG, et al. Probiotics modulate gut microbiota and improve insulin sensitivity in DIO mice. J Nutr Biochem. 2017; 50: 16-25.
- 35Younossi ZM, Baranova A, Ziegler K, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology. 2005; 42: 665-674.
- 36Rinttila T, Kassinen A, Malinen E, Krogius L, Palva A. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol. 2004; 97: 1166-1177.
- 37Guo X, Xia X, Tang R, Zhou J, Zhao H, Wang K. Development of a real-time PCR method for Firmicutes and Bacteroidetes in faeces and its application to quantify intestinal population of obese and lean pigs. Lett Appl Microbiol. 2008; 47: 367-373.
- 38Nepomuceno R, Pigossi SC, Finoti LS, et al. Serum lipid levels in patients with periodontal disease: a meta-analysis and meta-regression. J Clin Periodontol. 2017; 44(12): 1192-1207.
- 39Choi YH, Kosaka T, Ojima M, et al. Relationship between the burden of major periodontal bacteria and serum lipid profile in a cross-sectional Japanese study. BMC Oral Health. 2018; 18: 77.
- 40Pontes Andersen CC, Buschard K, Flyvbjerg A, Stoltze K, Holmstrup P. Periodontitis deteriorates metabolic control in type 2 diabetic Goto-Kakizaki rats. J Periodontol. 2006; 77: 350-356.
- 41Watanabe K, Petro BJ, Shlimon AE, Unterman TG. Effect of periodontitis on insulin resistance and the onset of type 2 diabetes mellitus in Zucker diabetic fatty rats. J Periodontol. 2008; 79: 1208-1216.
- 42Liu Y, Zhang Q. Periodontitis aggravated pancreatic β-cell dysfunction in diabetic mice through interleukin-12 regulation on Klotho. J Diabetes Investig. 2016; 7: 303-311.
- 43Xynogala I, Pepelassi E, Perrea D, et al. Adiponectin and interleukin-6 levels in insulin-treated diabetic rats with experimental periodontitis. Braz Oral Res. 2012; 26: 71-76.
- 44Chen J, Wang R, Li X-F, Wang R-L. Bifidobacterium adolescentis supplementation ameliorates visceral fat accumulation and insulin sensitivity in an experimental model of the metabolic syndrome. Br J Nutr. 2012; 107: 1429-1434.
- 45Wang J, Tang H, Zhang C, et al. Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME J. 2015; 9: 1-15.
- 46Guo Z, Liu XM, Zhang QX, et al. Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomised controlled trials. Nutr Metab Cardiovasc Dis. 2011; 21: 844-850.
- 47Yoo SR, Kim YJ, Park DY, et al. Probiotics L. plantarum and L. curvatus in combination alter hepatic lipid metabolism and suppress diet-induced obesity. Obesity (Silver Spring). 2013; 21: 2571-2578.
- 48Gao D, Zhu G, Gao Z, Liu Z, Wang L, Guo W. Antioxidative and hypolipidemic effects of lactic acid bacteria from pickled Chinese cabbage. J Med Plants Res. 2011; 5: 1439-1446.
- 49Karimi G, Jamaluddin R, Mohtarrudin N, Ahmad Z, Khazaai H, Parvaneh M. Single-species versus dual-species probiotic supplementation as an emerging therapeutic strategy for obesity. Nutr Metab Cardiovasc Dis. 2017; 27: 910-918.
- 50Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A. Mechanisms of action of probiotics. Adv Nutr. 2019; 10: S49-s66.
- 51Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009; 58: 1091-1103.
- 52Miglioranza Scavuzzi B, Miglioranza LHS, Henrique FC, et al. The role of probiotics on each component of the metabolic syndrome and other cardiovascular risks. Expert Opin Ther Targets. 2015; 19: 1127-1138.
- 53Alakhali MS, Al-Maweri SA, Al-Shamiri HM, Al-Haddad K, Halboub E. The potential association between periodontitis and non-alcoholic fatty liver disease: a systematic review. Clin Oral Investig. 2018; 22: 2965-2974.
- 54Li HL, Wu X, Xu A, Hoo RL. A-FABP in metabolic diseases and the therapeutic implications: an update. Int J Mol Sci. 2021; 22:9386.
- 55Deeb A, Attia S, Mahmoud S, Elhaj G, Elfatih A. Dyslipidemia and fatty liver disease in overweight and obese children. J Obes. 2018; 2018:8626818.
- 56Zhang M, Deng Q, Wang L, et al. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: a nationally representative survey of 163,641 adults. Int J Cardiol. 2018; 260: 196-203.
- 57Kim OS, Shin MH, Kweon SS, et al. The severity of periodontitis and metabolic syndrome in Korean population: the Dong-gu study. J Periodontal Res. 2018; 53: 362-368.
- 58Gonçalves TO, Costa D, Brodskyn CI, Duarte PM, César Neto JB, Nogueira-Filho G. Release of cytokines by stimulated peripheral blood mononuclear cells in chronic periodontitis. Arch Oral Biol. 2010; 55: 975-980.
- 59Matsuda Y, Kato T, Takahashi N, et al. Ligature-induced periodontitis in mice induces elevated levels of circulating interleukin-6 but shows only weak effects on adipose and liver tissues. J Periodontal Res. 2016; 51: 639-646.
- 60Hendek MK, Erdemir EO, Kisa U, Ozcan G. Effect of initial periodontal therapy on oxidative stress markers in gingival crevicular fluid, saliva, and serum in smokers and non-smokers with chronic periodontitis. J Periodontol. 2015; 86: 273-282.
- 61Grant MM, Brock GR, Matthews JB, Chapple IL. Crevicular fluid glutathione levels in periodontitis and the effect of non-surgical therapy. J Clin Periodontol. 2010; 37: 17-23.
- 62Tonguç M, Öztürk O, Sütçü R, et al. The impact of smoking status on antioxidant enzyme activity and malondialdehyde levels in chronic periodontitis. J Periodontol. 2011; 82: 1320-1328.
- 63Tomofuji T, Ekuni D, Sanbe T, et al. Effects of improvement in periodontal inflammation by toothbrushing on serum lipopolysaccharide concentration and liver injury in rats. Acta Odontol Scand. 2009; 67: 200-205.
- 64Tomofuji T, Ekuni D, Yamanaka R, et al. Chronic administration of lipopolysaccharide and proteases induces periodontal inflammation and hepatic steatosis in rats. J Periodontol. 2007; 78: 1999-2006.
- 65Crespo J, Cayón A, Fernández-Gil P, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 2001; 34: 1158-1163.
- 66Araújo AA, Souza TO, Moura LM, et al. Effect of telmisartan on levels of IL-1, TNF-α, down-regulated COX-2, MMP-2, MMP-9 and RANKL/RANK in an experimental periodontitis model. J Clin Periodontol. 2013; 40: 1104-1111.
- 67Miyoshi M, Ogawa A, Higurashi S, Kadooka Y. Anti-obesity effect of Lactobacillus gasseri SBT2055 accompanied by inhibition of pro-inflammatory gene expression in the visceral adipose tissue in diet-induced obese mice. Eur J Nutr. 2014; 53: 599-606.
- 68He J, Zhang F, Han Y. Effect of probiotics on lipid profiles and blood pressure in patients with type 2 diabetes: a meta-analysis of RCTs. Medicine. 2017; 96:e9166.
- 69Asgharian A, Askari G, Esmailzade A, Feizi A, Mohammadi V. The effect of symbiotic supplementation on liver enzymes, C-reactive protein and ultrasound findings in patients with non-alcoholic fatty liver disease: a clinical trial. Int J Prev Med. 2016; 7: 59.
- 70Mofidi F, Poustchi H, Yari Z, et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr. 2017; 117: 662-668.
- 71Bakhshimoghaddam F, Shateri K, Sina M, Hashemian M, Alizadeh M. Daily consumption of synbiotic yogurt decreases liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. J Nutr. 2018; 148: 1276-1284.
- 72Kobyliak N, Abenavoli L, Falalyeyeva T, et al. Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study. Minerva Med. 2018; 109: 418-428.
- 73Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003; 37: 343-350.
- 74Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014; 99: 535-542.
- 75Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K. Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the West Virginian population. Int J Med Sci. 2016; 13: 25-38.
- 76Haugen F, Drevon CA. Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin. Endocrinology. 2007; 148: 5478-5486.
- 77Damanaki A, Nokhbehsaim M, Eick S. Regulation of NAMPT in human gingival fibroblasts and biopsies. Mediators Inflamm. 2014; 2014:912821.
- 78Luo S, Yang X, Wang D, et al. Periodontitis contributes to aberrant metabolism in type 2 diabetes mellitus rats by stimulating the expression of adipokines. J Periodontal Res. 2016; 51: 453-461.
- 79Park KH, Kim D-K, Huh YH, et al. NAMPT enzyme activity regulates catabolic gene expression in gingival fibroblasts during periodontitis. Exp Mol Med. 2017; 49:e368.
- 80Hassan B, Baroukh B, Llorens A, et al. NAMPT expression in osteoblasts controls osteoclast recruitment in alveolar bone remodeling. J Cell Physiol. 2018; 233(9): 7402-7414.
- 81Adamczak M, Wiecek A. The adipose tissue as an endocrine organ. Semin Nephrol. 2013; 33: 2-13.
- 82Bullon P, Newman HN, Battino M. Obesity, diabetes mellitus, atherosclerosis and chronic periodontitis: a shared pathology via oxidative stress and mitochondrial dysfunction? Periodontology 2000. 2014; 64: 139-153.
- 83Rocha-Ramírez LM, Hernández-Chiñas U. Probiotic properties and immunomodulatory activity of Lactobacillus strains isolated from dairy products. Microorganisms. 2021; 9(4): 825.
- 84Rocha-Ramírez LM, Pérez-Solano RA. Probiotic Lactobacillus strains stimulate the inflammatory response and activate human macrophages. J Immunol Res. 2017; 2017:4607491.
- 85Doğan B, Kemer Doğan ES. Synergistic effect of omega-3 and probiotic supplementation on preventing ligature-induced periodontitis. Probiotics Antimicrob Proteins. 2022; 14(1): 114-120.
- 86Ondee T, Pongpirul K. Lactiplantibacillus plantarum dfa1 outperforms Enterococcus faecium dfa1 on anti-obesity in high fat-induced obesity mice possibly through the differences in gut dysbiosis attenuation, despite the similar anti-inflammatory properties. Nutrients. 2021; 14(1): 80.
- 87Musazadeh V, Zarezadeh M, Ghalichi F, et al. Anti-obesity properties of probiotics; a considerable medical nutrition intervention: findings from an umbrella meta-analysis. Eur J Pharmacol. 2022; 928:175069.
- 88Zhang Z, Zhou Z, Li Y, Zhou L, Ding Q, Xu L. Isolated exopolysaccharides from Lactobacillus rhamnosus GG alleviated adipogenesis mediated by TLR2 in mice. Sci Rep. 2016; 6:36083.
- 89Zhang C, Zhu R, Wang H, et al. Nicotinamide phosphate transferase (NAMPT) increases in plasma in patients with acute coronary syndromes, and promotes macrophages to M2 polarization. Int Heart J. 2018; 59: 1116-1122.
- 90Laight DW, Kengatharan KM, Gopaul NK, Anggård EE, Carrier MJ. Investigation of oxidant stress and vasodepression to glyceryl trinitrate in the obese Zucker rat in vivo. Br J Pharmacol. 1998; 125: 895-901.
- 91Foureaux Rde C, Messora MR, de Oliveira LF, et al. Effects of probiotic therapy on metabolic and inflammatory parameters of rats with ligature-induced periodontitis associated with restraint stress. J Periodontol. 2014; 85: 975-983.
- 92Gerhard D, Sousa F, Andraus RAC, et al. Probiotic therapy reduces inflammation and improves intestinal morphology in rats with induced oral mucositis. Braz Oral Res. 2017; 31:e71.
- 93Levi Y, Novais GS, Dias RB, Andraus RAC, Messora MR. Effects of the prebiotic mannan oligosaccharide on the experimental periodontitis in rats. J Clin Periodontol. 2018; 45(9): 1078-1089.
- 94de Oliveira AM, Lourenço TGB. Impact of systemic probiotics as adjuncts to subgingival instrumentation on the oral-gut microbiota associated with periodontitis: a randomized controlled clinical trial. J Periodontol. 2022; 93(1): 31-44.
- 95Lewis B, Mukewar S, Lopez R, Brzezinski A, Hall P, Shen B. Frequency and risk factors of renal insufficiency in inflammatory bowel disease inpatients. Inflamm Bowel Dis. 2013; 19: 1846-1851.
- 96Jakobsson HE, Rodríguez-Piñeiro AM, Schütte A, et al. The composition of the gut microbiota shapes the colon mucus barrier. EMBO Rep. 2015; 16: 164-177.
- 97Vives-Soler A, Chimenos-Küstner E. Effect of probiotics as a complement to non-surgical periodontal therapy in chronic periodontitis: a systematic review. Med Oral Patol Oral Cir Bucal. 2020; 25: e161-e167.
- 98Wang B, Gong L, Zhou Y, et al. Probiotic Paenibacillus polymyxa 10 and Lactobacillus plantarum 16 enhance growth performance of broilers by improving the intestinal health. Anim Nutr. 2021; 7: 829-840.
- 99Gillor O, Etzion A, Riley MA. The dual role of bacteriocins as anti- and probiotics. Appl Microbiol Biotechnol. 2008; 81: 591-606.
- 100Gordon DM. The potential of bacteriocin-producing probiotics and associated caveats. Future Microbiol. 2009; 4(8): 941-943.
- 101Stamatova I, Meurman JH. Probiotics and periodontal disease. Periodontology 2000. 2009; 51: 141-151.
- 102Miglioranza Scavuzzi B, Miglioranza LH, Henrique FC, et al. The role of probiotics on each component of the metabolic syndrome and other cardiovascular risks. Expert Opin Ther Targets. 2015; 19: 1127-1138.
- 103Teughels W, Durukan A, Ozcelik O, Pauwels M, Quirynen M, Haytac MC. Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis: a randomized placebo-controlled study. J Clin Periodontol. 2013; 40: 1025-1035.
- 104Teughels W, Loozen G, Quirynen M. Do probiotics offer opportunities to manipulate the periodontal oral microbiota? J Clin Periodontol. 2011; 38(Suppl 1): 159-177.
- 105Akbari V, Hendijani F. Effects of probiotic supplementation in patients with type 2 diabetes: systematic review and meta-analysis. Nutr Rev. 2016; 74: 774-784.
- 106Hu YM, Zhou F, Yuan Y, Xu YC. Effects of probiotics supplement in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. Medicina Clinica. 2017; 148: 362-370.
- 107Liang T, Wu L, Xi Y, et al. Probiotics supplementation improves hyperglycemia, hypercholesterolemia, and hypertension in type 2 diabetes mellitus: an update of meta-analysis. Crit Rev Food Sci Nutr. 2021; 61: 1670-1688.
- 108Ruan Y, Sun J, He J, Chen F, Chen R, Chen H. Effect of probiotics on glycemic control: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2015; 10:e0132121.
- 109Samah S, Ramasamy K, Lim SM, Neoh CF. Probiotics for the management of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2016; 118: 172-182.
- 110Khalesi S, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension. 2014; 64: 897-903.
